The Architecture of Resistance and Memory: A Dual-Domain Odyssey of CCR5
Future Journal of Pharmaceuticals and Health Sciences · 15.10.2026 · 6 (4) · 54-65
DOI: 10.26452/fjphs.v6i4.941 ↗Kurz gefasst
Fachartikel in der Zeitschrift Future Journal of Pharmaceuticals and Health Sciences, online erschienen am 15.10.2026. Verfasst von {"name":"Karthik Unnikrishnan","email":"robin.george793@gmail.com","affiliati und 1 weiteren Autor:innen.
Abstract (Originalsprache)
CCR5 is a chemokine receptor involved in immune-cell trafficking and serves as a major coreceptor for entry of CCR5-tropic HIV-1. The naturally occurring 32-base-pair deletion, CCR5-Δ32, can substantially reduce susceptibility to R5 HIV-1 when present in the homozygous state, while CCR5 signalling has also been implicated in neuroplasticity and memory. To review the biology and inheritance of CCR5-Δ32, its relationship with HIV acquisition and disease progression, the evolutionary and immunological implications of CCR5 deficiency, and emerging therapeutic applications in HIV remission and neurological recovery. This narrative review synthesizes the literature and clinical reports cited in the source manuscript, spanning CCR5 structure and function, HIV virology, genetic association studies, transplantation, gene editing, pharmacological blockade, and experimental neuroscience. It is not a new clinical study or systematic review. Homozygous CCR5-Δ32 is strongly protective against CCR5-tropic HIV-1 but does not provide universal immunity because HIV may use alternative coreceptors. CCR5-targeted transplantation and gene-editing approaches provide important proof of principle, yet remain limited by clinical risk, feasibility, and access. Experimental studies also associate CCR5 signalling with learning, memory linking, and recovery after neurological injury; these findings should not be interpreted as established cognitive treatments. CCR5 illustrates how a single receptor can connect infectious disease, immune function, and neurobiology. Translation of CCR5-related discoveries requires careful evidence appraisal, attention to biological trade-offs, ethical oversight, and equitable access.
Zitieren
APA
Unnikrishnan","email":"robin.george793@gmail.com","affiliati, N., & George","email":"robin.george793@gmail.com","affiliation":"I, N. (2026). The Architecture of Resistance and Memory: A Dual-Domain Odyssey of CCR5. Future Journal of Pharmaceuticals and Health Sciences, 6(4), 54-65. https://doi.org/10.26452/fjphs.v6i4.941
Vancouver
Unnikrishnan","email":"robin.george793@gmail.com","affiliati N, George","email":"robin.george793@gmail.com","affiliation":"I N. The Architecture of Resistance and Memory: A Dual-Domain Odyssey of CCR5. Future Journal of Pharmaceuticals and Health Sciences. 2026;6(4):54-65. doi:10.26452/fjphs.v6i4.941
BibTeX
@article{Unnikrishnanemailrobingeorgegmailcomaffiliati2026,
author = {Unnikrishnan","email":"robin.george793@gmail.com","affiliati, "name":"Karthik and George","email":"robin.george793@gmail.com","affiliation":"I, "name":"Robin},
title = {The Architecture of Resistance and Memory: A Dual-Domain Odyssey of CCR5},
journal = {Future Journal of Pharmaceuticals and Health Sciences},
year = {2026},
volume = {6},
number = {4},
pages = {54--65},
doi = {10.26452/fjphs.v6i4.941}
}
EUVIMED